<ul><li>SpotitEarly, a biotech company, has entered the U.S. market with $20.3 million funding for its AI and canine-powered cancer detection test.</li><li>The company utilizes a breath-based diagnostic platform that combines advanced AI with canine scent detection to identify cancer-associated volatile organic compounds with 94% accuracy.</li><li>SpotitEarly's at-home test targets breast, colorectal, prostate, and lung cancers, providing a cost-effective and accessible alternative to invasive screening methods.</li><li>The company has received funding from investors and grants, and is expanding its scientific leadership while establishing partnerships with U.S. academic medical centers.</li></ul>

SpotitEarly Enters U.S. Market with $20.3M for AI & Canine-Powered Cancer Test

Discover more